Kimball Electronics, Inc.

What they do

Kimball Electronics manufactures electronic assemblies and other products, including medical devices, medical disposables, and precision molded plastics, to customer specifications. Its CMO solutions support the production of medical disposables and drug delivery devices, from precision molded plastics and cold chain management to drug integration. The company operates manufacturing facilities in the United States, China, Mexico, Poland, Romania, and Thailand, with a largely standardized global operating system.

Revenue drivers

• Medical vertical — Fiscal 2026 medical sales increased over 10% (normalized for a consigned inventory sale) and are expected to represent more than one-third of total sales in fiscal 2027.
• Automotive vertical — Q4 fiscal 2026 automotive sales decreased 3% year-over-year; historically a major end market for the company.
• Industrial vertical — Q4 fiscal 2026 industrial sales decreased 5% year-over-year; another primary end market.
• Helvoet Polymer Technologies acquisition — Acquired to expand medical CDMO capabilities; expected to contribute approximately $60 million in sales in fiscal 2027.

Recent performance

In Q4 fiscal 2026, net sales were $371.6 million, up 5% sequentially, with all end-market verticals posting gains. Operating income was $29.1 million (7.8% of net sales) with adjusted operating income margin of 4.9%. Full-year fiscal 2026 net sales totaled $1,431.4 million; operating income was $66.1 million (4.6% of net sales). The company generated $42.4 million cash from operations in Q4, the tenth consecutive quarter of positive operating cash generation, and ended the quarter with $88.9 million cash and $116.6 million debt, the lowest debt in over four years.

Strategy

Management is focused on strategic investments in the medical CDMO space, including the buildout of a new medical facility in Indianapolis and the acquisition of Helvoet Polymer Technologies. The company aims to balance its portfolio across markets, with medical expected to outpace other verticals and represent more than one-third of sales. Fiscal 2027 guidance projects a return to top-line growth, leveraging a strengthened balance sheet with borrowing capacity of $322.4 million and available cash. The company also repurchased shares, investing $11.9 million to buy 447,000 shares in fiscal 2026.

Risks

• Key customer concentration — Loss of or significant volume reduction from key customers could materially reduce revenues and profitability; customers do not commit to firm production schedules beyond one quarter.
• Fixed cost base — Because many costs and operating expenses are relatively fixed, a reduction in customer demand can harm gross profit margins and results.
• Customer cancellation rights — Customers generally have the right to cancel a particular product, subject to contractual provisions, which could disrupt revenue and require inventory write-downs.
• Execution on growth investments — The buildout of the new medical facility and integration of Helvoet introduce execution risk that could affect returns on investment and operating results.

Outlook

For fiscal 2027, management guides net sales of $1,535-$1,560 million, a 7%-9% increase over fiscal 2026, with organic sales growth of 3%-5% and medical increasing in the high single to low double-digit range. Helvoet is expected to add approximately $60 million in sales. Adjusted operating income is guided at 4.4%-4.7% of net sales, with capital expenditures of $50-$60 million.